• Cellceutix Corp., of Beverly, Mass., said preclinical research into the mechanism of action of Kevetrin showed that the drug not only activates p53 but targets HDAC2. Kevetrin down-regulated HDAC2 in mutant and null p53 cancer cell lines. Clinical trials in cancer are expected to start this year.